Signs of LifeWhat is that 4 PRs in the last month? This reminds me of a time about 5 years ago when the company regularly did PRs.
Perhaps the first signs of life from management in a long time.
Contrary to posts from others there is no advantage in waiting before applying for BTD. Since the August 2022 phase 2 update the company has met the conditions for getting BTD as outlined repeatedly by the company; the numbers were already there. Five months later still waiting.
I don't believe there is any one who doesn't believe the company has the numbers and safety profile to achieve BTD so I am starting to doubt it will have a material change in the share price when it finally arrives. The next trial update will not materialy change the numbers at 450 days wither than add more weight to the optimized treated group versus the unoptimized group. In fact some have already started to speculate as to what those numbers might show.
BTD had more value to the company as a means to further the use of PDT in treating bladder cancer. BTD offeres credibility and greater expectations that suitable candidates will choose the Theralase phase 2 trial and get us through to eventual FDA approval.
What the market wants to see is a pathway to AA so we can finish the trial without another significant dilution. AA provides an income stream and the potential for debt financing if we continue going it alone.
AA will increase company revenues and is the real prize that is most likely to drive the share price higher and keep it there in the next year.
Lots of things might happen from Roger coming back, talks about a JV, results of the vaccine initiative and new phase 1 trials - these will provide opportunities for stimulating interest in the company and fodder for PRs to come.
Branding our bladder treatment drug and increasing PRs are signs that management might just be turning the page. We need more people interested in Theralase to expand the pool of shareholders, stimulate interest in potential JV partners and most importantly get the word out about an innovative way to treat cancer.